Advertisement

Topics

BIND Biosciences, Inc. Company Profile

20:21 EST 12th December 2018 | BioPortfolio

BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide significant improvement in the treatment of patients with serious diseases. BIND’s platform enables the design, engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics, biodistribution, and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective, and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications or life cycle extension for mid- and late-stage products. BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.


News Articles [665 Associated News Articles listed on BioPortfolio]

Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion

Illumina, Inc. and Pacific Biosciences announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction....

Strategic partnership forms between Taconic Biosciences and Cyagen Biosciences

A strategic partnership has been formed between Taconic Biosciences and Cyagen Biosciences — both global companies that generate custom genetically engineered rodent models and associated services.

Illumina To Acquire Pacific Biosciences At $8.00/shr

SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN) and Pacific Biosciences (PACB) announced an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in a...

Kuros Biosciences Ltd.: Kuros Biosciences appoints Strategic Advisory Board

Kuros Biosciences appoints Strategic Advisory Board Schlieren (Zurich), Switzerland, September 25, 2018 - Kuros Biosciences (SIX: KURN) today announced the formation of its Strategic Advisory Boar...

Kuros Biosciences Ltd.: Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer

Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer Schlieren (Zurich), Switzerland, August 23, 2018 Kuros Biosciences AG (SIX: KURN) announced today the appointment of Pascal Long...

LD Micro - Artelo BioSciences

"Artelo Biosceinces Inc (OTCMKTS:ARTL) sat down with Proactive Investors at the 11th Annual LD Micro Main Event in Los Angeles to bring investors up to date on the company's accomplishments. The com...

FSD Pharma to acquire Therapix Biosciences

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Bios...

Illumina to acquire Pacific Biosciences for $1.2bn

California-based Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems The company’s technology is claimed to offer high accuracy, ultra-long read...

Drugs and Medications [22 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [229 Associated PubMed Articles listed on BioPortfolio]

Resetting the ligand binding site of placental protein 13/galectin-13 recovers its ability to bind lactose.

Placental protein-13 / galectin-13 (Gal-13) is highly expressed in placenta, where its lower expression is related to pre-eclampsia. Recently, the crystal structures of wild type Gal-13 and its varian...

Contents list.

Front cover.

Back cover.

Optimizing the utility of the individual development plan for trainees in the biosciences.

Clinical Trials [117 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis

Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment fo...

Long-Term Follow Up Study

The LTFU study will conduct a naturalistic follow up of the well characterized CAN-BIND study population of patients every six months and continuing over a five-year period. This will prov...

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cel...

Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum

The purpose of this study is to test the safety of a new medicine called antibody 8H9 injected into the lining of the abdomen or peritoneum, where the tumor is. This medicine is an antibod...

Companies [404 Associated Companies listed on BioPortfolio]

BIND Biosciences, Inc.

BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide signif...

BIND Therapeutics, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering pl...

BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Me...

Alzeca Biosciences, Inc.

Alzeca Biosciences is an early-stage company focused on developing novel, proprietary, targeted MRI imaging agents for the early diagnosis of Alzheimer’s disease and other ne...

BIND Therapeutics and Navidea Biopharmaceuticals

BIND Therapeutics is a clinical-stage nanomedicine platform company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration...

More Information about "BIND Biosciences, Inc." on BioPortfolio

We have published hundreds of BIND Biosciences, Inc. news stories on BioPortfolio along with dozens of BIND Biosciences, Inc. Clinical Trials and PubMed Articles about BIND Biosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BIND Biosciences, Inc. Companies in our database. You can also find out about relevant BIND Biosciences, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record